Navigation Links
/C O R R E C T I O N -- Mobidiag Ltd/
Date:4/21/2008

Mobidiag Releases First Microarray Based Rapid Test for Bacterial Detection

The Finnish biotechnology company Mobidiag announced today the Prove-it(TM) Bacteria test that sets a world record by being able to detect 50 dangerous bacteria simultaneously - including the widespread "superbug" MRSA. This is an important milestone in the battle against infectious diseases, most importantly life-threatening sepsis.

HELSINKI, April 21 /PRNewswire/ -- Sepsis is a growing cause of death worldwide - there are around 3 million sepsis cases annually, over 500,000 of them resulting in death. Sepsis is an infection caused by a number of micro-organisms spreading in the bloodstream. The challenge in sepsis treatment is starting adequate treatment with the appropriate antibiotics on time.

Currently, the diagnostics of causative pathogen(s) needed for the antibiotic treatment decision takes 2-5 days based on blood culturing and subsequent pathogen identification. Using Mobidiag's Prove-it(TM) Bacteria, the pathogen detection is available 1-3 days earlier compared to current diagnostics. The PCR and microarray-based test takes less than three hours to complete. Achieved time saving rationalizes antibiotic treatment and improves patient outcomes and decreases mortality considerably.

"Our Prove-it(TM) Bacteria test has all the potential to revolutionize microbial sepsis diagnostics. The test helps clinicians make better and faster decisions and provide sufficient treatment for seriously ill patients. This offers huge savings, as sepsis treatment currently consumes billions of euros annually. Our target is to have a single test that reliably detects the majority of dangerous human disease causing bacteria and Prove-it(TM) Bacteria test is an important milestone on that road," says Jaakko Pellosniemi, CEO of Mobidiag. "I strongly believe that Prove-it(TM) products will rapidly gain foothold on the multibillion microbial diagnostic markets."

Prove-it(TM) Bacteria test is initially intended for research purposes. The evaluation aiming for the European CE-IVD status enabling its use in clinical sepsis diagnostics is currently ongoing and will be completed later this year. The test will cover more than 90 % of all sepsis cases.

Founded in 2001, Mobidiag develops rapid diagnostic tests for hospital laboratories. The Prove-it(TM) Bacteria test is developed in co-operation with HUSLAB and Hospital Districts of Helsinki and Uusimaa, Finland.

Mobidiag Ltd is a Finnish biotechnology company developing, producing and marketing rapid diagnostic tests to hospital laboratories. The company focuses on clinical microbial diagnostics. More information on http://www.mobidiag.com
Press photos from here http://www.mobidiag.com/media/images

Additional information:

CEO Jaakko Pellosniemi, Mobidiag Ltd, tel. +358-40-501-1004

Press contact:

Ville Lehtovirta, Text 100 Conexio, tel. +358-50-346-6946

ville.lehtovirta@conexio.fi


'/>"/>
SOURCE Mobidiag Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):